Oligonucleotide · developed by Sarepta Therapeutics
AVI-7288 is an agent given by intravenous infusion, studied in Marburg hemorrhagic fever.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01566877 | Phase 1 | Marburg Hemorrhagic Fever | Completed | SRPT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Marburg Hemorrhagic Fever
Updated Nov 1, 2026. Something wrong or missing? Report it on the SRPT page.
See SRPT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SRPT catalysts and pipeline →